AnaCardio
AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility and aims to improve clinical outcomes in heart failure.
$70.97M Series B+ ·
Led by Novo Holdings · Source: anacardio.com
Total raised: $89.97M across 2 sourced rounds
All 3 rounds ↓Signals
AnaCardio | 1531 days on the record
Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | $70.97M | anacardio.com | ||
| Series A | $19M | fundraisingfox.com | ||
| Series A | undisclosed | fundraisingfox.com |
Timeline
- Website created
Team
PS
Patrik Stromberg CEOPM
Philipp Mathieu Chief Financial Officer
Investors
- 33B Ventures
- AAnnHelene Ljungström
FFlerie Investlead investor
- FFredrik Ljungström
HHelsinn Healthcare
IIndustrifondenlead investor
IInnovestor
- LLLD Nybohov Invest AB
NNovo Holdingslead investor
PPureos Bioventureslead investor
SSound Bioventureslead investor
- TThe Ljungstrom Family Officelead investor
Companies like AnaCardio
CCytoHubPre Seed · Mar 2026
AAIKONSeries A · Sep 2022
SSensibleSeed · Nov 2022CcaVos biotherapeuticsSeed · Mar 2026
CCatalYm$150M Series B+ · Jul 2024
SSEISMIC PharmaceuticalsSeed · Mar 2026
Other companies backed by Novo Holdings
OOMass Therapeutics$310M Series B+ · Oct 2026
BBreye Therapeutics$76.65M Series A · Sep 2026
CClaris Bio$118M Series B+ · Jul 2026
BBactolife$34.9M Series B+ · Jan 2026
SSidera Bio$109.99M Series A · Nov 2025
PPhasecraft$34M Series B+ · Oct 2025
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/anacardio (get a free API key).